{"title":"非转移性乳腺癌辅助超低分割放疗的真实世界安全性：急性皮肤毒性和美学结果。","authors":"Molka Mezghani, Mouna Ben Rejeb, Awatef Hamdoun, Rihab Haddad, Ghada Bouguerra, Lilia Ghorbal, Lotfi Kochbati","doi":"10.1016/j.clbc.2025.08.007","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>Ultra-hypofractionated radiotherapy (U-HFRT) delivers a total dose in five fractions over one week and represents an emerging approach in the adjuvant treatment of breast cancer. However, concerns about toxicity continue to limit its widespread adoption in routine clinical practice. Skin toxicity, one of the most common side effects of breast RT, can significantly affect patients' quality of life and may lead to treatment interruptions.</p><p><strong>Objective: </strong>This prospective cohort study aimed to evaluate acute skin toxicity and aesthetic outcomes following U-HFRT and to identify predictive factors.</p><p><strong>Methods: </strong>A total of 102 patients who underwent breast-conserving surgery or mastectomy for localized breast cancer were included. Adjuvant RT was delivered at a dose of 26 Gy in 5 fractions over 1 week. A sequential boost of 10 Gy in 5 fractions was delivered to the tumor bed in selected patients who received whole-breast irradiation. Skin toxicity was assessed according to the CTCAE 4.03 scale, and aesthetic outcomes were evaluated using the Harvard classification.</p><p><strong>Results: </strong>The median age was 59.5 years. No radiodermatitis (RD) was observed in 42% of patients, while grade 1 and grade 2 RD occurred in 38.2% and 18.6% of cases, respectively. Only one patient experienced grade 3 RD. The peak of toxicity occurred on the tenth day after RT. Induration of the tumor bed was noted in 9.6% of patients receiving a boost versus 14.6% without a boost. A breast volume ≥ 714 cm3 was significantly associated with the occurence of RD. Clinical target volume receiving 105% of the prescribed dose ≥ 4.23% was associated with grade 2 RD. Aesthetic outcomes improved after a median follow-up of 8 months.</p><p><strong>Conclusion: </strong>U-HFRT appears to be a feasible and well-tolerated adjuvant treatment, with acceptable skin toxicity rates andfavorable aesthetic outcomes. However, a longer follow-up is necessary to assess long-term toxicities.</p>","PeriodicalId":10197,"journal":{"name":"Clinical breast cancer","volume":" ","pages":""},"PeriodicalIF":2.5000,"publicationDate":"2025-08-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Real World Safety of Adjuvant Ultra Hypofractionated Radiotherapy in Nonmetastatic Breast Cancer: Acute Cutaneous Toxicity and Aesthetic Outcomes.\",\"authors\":\"Molka Mezghani, Mouna Ben Rejeb, Awatef Hamdoun, Rihab Haddad, Ghada Bouguerra, Lilia Ghorbal, Lotfi Kochbati\",\"doi\":\"10.1016/j.clbc.2025.08.007\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Background: </strong>Ultra-hypofractionated radiotherapy (U-HFRT) delivers a total dose in five fractions over one week and represents an emerging approach in the adjuvant treatment of breast cancer. However, concerns about toxicity continue to limit its widespread adoption in routine clinical practice. Skin toxicity, one of the most common side effects of breast RT, can significantly affect patients' quality of life and may lead to treatment interruptions.</p><p><strong>Objective: </strong>This prospective cohort study aimed to evaluate acute skin toxicity and aesthetic outcomes following U-HFRT and to identify predictive factors.</p><p><strong>Methods: </strong>A total of 102 patients who underwent breast-conserving surgery or mastectomy for localized breast cancer were included. Adjuvant RT was delivered at a dose of 26 Gy in 5 fractions over 1 week. A sequential boost of 10 Gy in 5 fractions was delivered to the tumor bed in selected patients who received whole-breast irradiation. Skin toxicity was assessed according to the CTCAE 4.03 scale, and aesthetic outcomes were evaluated using the Harvard classification.</p><p><strong>Results: </strong>The median age was 59.5 years. No radiodermatitis (RD) was observed in 42% of patients, while grade 1 and grade 2 RD occurred in 38.2% and 18.6% of cases, respectively. Only one patient experienced grade 3 RD. The peak of toxicity occurred on the tenth day after RT. Induration of the tumor bed was noted in 9.6% of patients receiving a boost versus 14.6% without a boost. A breast volume ≥ 714 cm3 was significantly associated with the occurence of RD. Clinical target volume receiving 105% of the prescribed dose ≥ 4.23% was associated with grade 2 RD. Aesthetic outcomes improved after a median follow-up of 8 months.</p><p><strong>Conclusion: </strong>U-HFRT appears to be a feasible and well-tolerated adjuvant treatment, with acceptable skin toxicity rates andfavorable aesthetic outcomes. However, a longer follow-up is necessary to assess long-term toxicities.</p>\",\"PeriodicalId\":10197,\"journal\":{\"name\":\"Clinical breast cancer\",\"volume\":\" \",\"pages\":\"\"},\"PeriodicalIF\":2.5000,\"publicationDate\":\"2025-08-19\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Clinical breast cancer\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1016/j.clbc.2025.08.007\",\"RegionNum\":3,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q2\",\"JCRName\":\"ONCOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Clinical breast cancer","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1016/j.clbc.2025.08.007","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"ONCOLOGY","Score":null,"Total":0}
Real World Safety of Adjuvant Ultra Hypofractionated Radiotherapy in Nonmetastatic Breast Cancer: Acute Cutaneous Toxicity and Aesthetic Outcomes.
Background: Ultra-hypofractionated radiotherapy (U-HFRT) delivers a total dose in five fractions over one week and represents an emerging approach in the adjuvant treatment of breast cancer. However, concerns about toxicity continue to limit its widespread adoption in routine clinical practice. Skin toxicity, one of the most common side effects of breast RT, can significantly affect patients' quality of life and may lead to treatment interruptions.
Objective: This prospective cohort study aimed to evaluate acute skin toxicity and aesthetic outcomes following U-HFRT and to identify predictive factors.
Methods: A total of 102 patients who underwent breast-conserving surgery or mastectomy for localized breast cancer were included. Adjuvant RT was delivered at a dose of 26 Gy in 5 fractions over 1 week. A sequential boost of 10 Gy in 5 fractions was delivered to the tumor bed in selected patients who received whole-breast irradiation. Skin toxicity was assessed according to the CTCAE 4.03 scale, and aesthetic outcomes were evaluated using the Harvard classification.
Results: The median age was 59.5 years. No radiodermatitis (RD) was observed in 42% of patients, while grade 1 and grade 2 RD occurred in 38.2% and 18.6% of cases, respectively. Only one patient experienced grade 3 RD. The peak of toxicity occurred on the tenth day after RT. Induration of the tumor bed was noted in 9.6% of patients receiving a boost versus 14.6% without a boost. A breast volume ≥ 714 cm3 was significantly associated with the occurence of RD. Clinical target volume receiving 105% of the prescribed dose ≥ 4.23% was associated with grade 2 RD. Aesthetic outcomes improved after a median follow-up of 8 months.
Conclusion: U-HFRT appears to be a feasible and well-tolerated adjuvant treatment, with acceptable skin toxicity rates andfavorable aesthetic outcomes. However, a longer follow-up is necessary to assess long-term toxicities.
期刊介绍：
Clinical Breast Cancer is a peer-reviewed bimonthly journal that publishes original articles describing various aspects of clinical and translational research of breast cancer. Clinical Breast Cancer is devoted to articles on detection, diagnosis, prevention, and treatment of breast cancer. The main emphasis is on recent scientific developments in all areas related to breast cancer. Specific areas of interest include clinical research reports from various therapeutic modalities, cancer genetics, drug sensitivity and resistance, novel imaging, tumor genomics, biomarkers, and chemoprevention strategies.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
